| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
ATR/Mec1: coordinating fork stability and repair
|
Friedel, Anna M
|
|
2009
|
21 |
2 |
p. 237-244
8 p.
|
artikel
|
| 2 |
Contents
|
|
|
2009
|
21 |
2 |
p. iii-
1 p.
|
artikel
|
| 3 |
Editorial Board
|
|
|
2009
|
21 |
2 |
p. i-
1 p.
|
artikel
|
| 4 |
ErbB receptors and signaling pathways in cancer
|
Hynes, Nancy E
|
|
2009
|
21 |
2 |
p. 177-184
8 p.
|
artikel
|
| 5 |
Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2
|
Reinhardt, H Christian
|
|
2009
|
21 |
2 |
p. 245-255
11 p.
|
artikel
|
| 6 |
Kinome signaling through regulated protein–protein interactions in normal and cancer cells
|
Pawson, Tony
|
|
2009
|
21 |
2 |
p. 147-153
7 p.
|
artikel
|
| 7 |
Linking somatic genetic alterations in cancer to therapeutics
|
Stuart, Darrin
|
|
2009
|
21 |
2 |
p. 304-310
7 p.
|
artikel
|
| 8 |
Mechanism of TGF-β signaling to growth arrest, apoptosis, and epithelial–mesenchymal transition
|
Heldin, Carl-Henrik
|
|
2009
|
21 |
2 |
p. 166-176
11 p.
|
artikel
|
| 9 |
mTOR and the control of whole body metabolism
|
Polak, Pazit
|
|
2009
|
21 |
2 |
p. 209-218
10 p.
|
artikel
|
| 10 |
Optimal targeting of the mTORC1 kinase in human cancer
|
Lane, Heidi A
|
|
2009
|
21 |
2 |
p. 219-229
11 p.
|
artikel
|
| 11 |
PI3K and mTOR inhibitors—a new generation of targeted anticancer agents
|
Brachmann, Saskia
|
|
2009
|
21 |
2 |
p. 194-198
5 p.
|
artikel
|
| 12 |
PIKKing on PKB: regulation of PKB activity by phosphorylation
|
Bozulic, Lana
|
|
2009
|
21 |
2 |
p. 256-261
6 p.
|
artikel
|
| 13 |
PKC inhibitors: potential in T cell-dependent immune diseases
|
Baier, Gottfried
|
|
2009
|
21 |
2 |
p. 262-267
6 p.
|
artikel
|
| 14 |
Protein kinase C intervention—the state of play
|
Roffey, Jon
|
|
2009
|
21 |
2 |
p. 268-279
12 p.
|
artikel
|
| 15 |
Protein kinases as antibacterial targets
|
Schreiber, Mark
|
|
2009
|
21 |
2 |
p. 325-330
6 p.
|
artikel
|
| 16 |
Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets
|
Knauf, Jeffrey A
|
|
2009
|
21 |
2 |
p. 296-303
8 p.
|
artikel
|
| 17 |
Should individual PI3 kinase isoforms be targeted in cancer?
|
Jia, Shidong
|
|
2009
|
21 |
2 |
p. 199-208
10 p.
|
artikel
|
| 18 |
Structural biology contributions to tyrosine kinase drug discovery
|
Cowan-Jacob, Sandra W
|
|
2009
|
21 |
2 |
p. 280-287
8 p.
|
artikel
|
| 19 |
Targeting protein kinases for the development of anti-inflammatory drugs
|
Cohen, Philip
|
|
2009
|
21 |
2 |
p. 317-324
8 p.
|
artikel
|
| 20 |
Targeting the EGFR and the PKB pathway in cancer
|
Klein, Shoshana
|
|
2009
|
21 |
2 |
p. 185-193
9 p.
|
artikel
|
| 21 |
Targeting the Kinome II
|
Hemmings, Brian A.
|
|
2009
|
21 |
2 |
p. 135-139
5 p.
|
artikel
|
| 22 |
The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl
|
Eck, Michael J
|
|
2009
|
21 |
2 |
p. 288-295
8 p.
|
artikel
|
| 23 |
Translating biology into clinic: the case of glioblastoma
|
Lino, Maddalena
|
|
2009
|
21 |
2 |
p. 311-316
6 p.
|
artikel
|
| 24 |
Tubers and tumors: rapamycin therapy for benign and malignant tumors
|
Plas, David R
|
|
2009
|
21 |
2 |
p. 230-236
7 p.
|
artikel
|
| 25 |
Tyrosine phosphorylation: thirty years and counting
|
Hunter, Tony
|
|
2009
|
21 |
2 |
p. 140-146
7 p.
|
artikel
|
| 26 |
VEGFs and receptors involved in angiogenesis versus lymphangiogenesis
|
Lohela, Marja
|
|
2009
|
21 |
2 |
p. 154-165
12 p.
|
artikel
|
Tijdschrift beschrijving